时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, an optimal treatment regimen is yet to be established.；This strategy, which relies on monthly visits to monitor disease activity, has limitations due to challenges with long-term follow- up.；Irregular follow-up can lead to treatment delays and worsen visual outcomes, highlighting the challenge of developing individualized regimens[6,11] .
方法
No.1 Youyi Road, Yuzhong District, Chongqing 400016, China. fancy_ mm@sina.com; pengh9@sina.com Received: 2025-06-03 Accepted: 2026-07-27 Abstract ● AIM: To evaluate and compare the efficacy and safety of two treat-and-extend (T&E) regimens (2- and 4-week intervals, Δ2w and Δ4w) of intravitreal conbercept injections in patients with neovascular age-related macular degeneration (nAMD). ● METHODS: This 24-month prospective randomized controlled trial at the First Affiliated Hospital of Chongqing Medical University included patients with nAMD.；The primary endpoint was the mean change in BCVA from baseline to the 2-year follow-up (noninferiority cutoff: 4 letters). ● RESULTS: Ultimately, 61 participants (68 eyes) completed the 2-year study.；Irregular follow-up can lead to treatment delays and worsen visual outcomes, highlighting the challenge of developing individualized regimens[6,11] .
核心结论
Eyes were randomly assigned (1:1) to receive intravitreal conbercept (0.5 mg) with T&E regimens using 2- or 4-week interval adjustments (Δ2w and Δ4w groups).；At week 96, the mean number of injections was 11.17±1.13 in the Δ2w group (36 eyes, with the mean age of 70.42±9.31y) and 9.84±1.02 in the Δ4w group (32 eyes, with the mean age of 71.25±9.99y; P<0.001).；No significant intergroup differences in vascular densities were observed. ‖ 结论：In conclusion, T&E regimens with 2- and 4-week intervals of intravitreal conbercept were effective in improving visual function in nAMD patients, with similar efficacy and safety profiles.
局限
This strategy, which relies on monthly visits to monitor disease activity, has limitations due to challenges with long-term follow- up.；Preliminary results at 24wk showed mean changes in BCVA of 7.28±7.75 and 2.15±3.83 letters for Δ2w and Δ4w groups, respectively.；Although multifocal electroretinogram was originally planned according to the study protocol as an additional functional outcome measure, it was not included in the final analysis due to pandemic-related logistical limitations and incomplete follow-up data collection.
对本项目的价值
★☆☆☆☆ 皮肤是唯一可直接局部给药、可活检、可影像量化的器官，最快可验证 senotherapeutic 概念。设计 randomized controlled trial。
全文来源
出版商 OA PDF（正文 43,159 字符，已过 DOI 逐字 / 标题指纹归属校验）
原文题录
- 英文标题：Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration.
- 期刊与标识：Int J Ophthalmol · PMID 42959616 · DOI 10.18240/ijo.2026.11.09
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。